“If you’re not on an AI highway to nirvana, then you may be on an AI highway to hell.”
— Dr. Debra Patt
She’s right—not literally—but the sentiment lands. The AI movement in oncology is moving fast, and while we haven’t reached nirvana yet, the direction we take will determine whether we accelerate progress or amplify chaos.
At Bridge Oncology, we aren’t standing on the sidelines watching this unfold. We are embedded in the very architecture of AI transformation across oncology. We have a proven, deep understanding of how these technologies are being built, why they’re being sold, and where the gaps still exist. The landscape is shifting dramatically—but the tactics behind it haven’t evolved as much as they should. And that’s exactly where our vantage point matters.
Beyond the Buzzwords: AI Built with Context
AI in cancer care cannot exist in a vacuum. It must be built with context, discipline, and an unwavering focus on the human behind the data. Too often, we see technology designed for technology’s sake—tools searching for a use case instead of solving a defined problem.
Dr. Sanjay Juneja, Chief Medical Officer of Tensor Black, recently framed the right question at the Association of Value-Based Cancer Care:
“Is this a solution to a pain point?”
That’s the lens we use every day at Bridge Oncology. Our teams have spent years in the trenches—mapping workflows, identifying integration barriers, advising on AI product development, and shaping health policy that defines the guardrails for safe and effective AI use. We see behind the curtain because we helped build the stage.
The Reality Behind the Curtain
1. Still Piecemeal
Despite the buzzwords—“end-to-end,” “fully integrated,” “complete solution”—most AI platforms are still a collection of loosely stitched applications. These stacks introduce massive hurdles in security vetting, IT integration, and pricing consistency.
We’ve analyzed dozens of systems across the country, and while some niche tools (for instance, AI contouring in head and neck) are extraordinary, most remain too narrow to justify enterprise-scale adoption.
2. Unfinished & Unsustainable
Departments are often paying full price for unfinished products. It can take six to twelve months just to “tune” AI systems to perform as promised. Many of these products were built for closed vendor ecosystems—not for the real-world, multi-system workflows where oncology teams actually operate.
Even large corporate-backed or PE-owned companies are facing an uncomfortable reality: scaling quickly for EBITDA targets rarely aligns with clinical sustainability. The result? Users get trapped in “limbo land” between promise and performance.
3. The EPIC Myth
Let’s be honest: there’s no such thing as full EPIC integration.
EPIC doesn’t allow true write-back capabilities into its system, and there’s no single unified gateway. Anyone claiming otherwise is either misinformed or overselling. Each connection is unique, each configuration bespoke. Real interoperability takes far more than an API handshake—it takes strategic design thinking across clinical, billing, and compliance layers.
Our View from the Front Lines
We’ve seen the AI ecosystem evolve from simple automation tools to multi-modal platforms that now promise to transform care delivery, documentation, and prior authorization. But the differentiator today isn’t who can say “AI”—it’s who can deliver secure, sustainable, and workflow-ready solutions that function on day one.
Bridge Oncology operates where policy, practice, and product intersect.
We help hospitals, health systems, and technology firms with the following:
Legal & Regulatory Savvy
Bridge Oncology brings an unusually deep understanding of the intersection between oncology services and regulatory/legal frameworks. When AI-driven tools or workflows are proposed, we can foresee not just the clinical and operational implications, but also the liability, scope-of-practice, reimbursement and compliance risks. Our holistic ensures that AI initiatives are built on firm legal footing—rather than being an afterthought.
AI Adoption Strategy
AI tooling in healthcare often stalls because of clinician resistance, workflow disruption, or unclear value-case. Bridge Oncology differentiates itself by blending deep operational and clinical domain expertise (especially radiation oncology) with AI strategy. We know how to design adoption pathways: from stakeholder alignment through pilot, metrics, scaling. We don’t just drop a “cool AI” into a department — we embed it in the workflow, map outcome touch-points (throughput, quality, cost), and align incentives so the adoption can be sustainable.
AI Software Vetting and Differentiation
There are hundreds of point-solutions claiming AI in oncology or radiation-oncology-adjacent fields. Bridge Oncology has the expertise to identify and differentiate between those point-solutions—evaluating not only the algorithmic claims but workflow fit, data-requirements, output interpretability, cost of implementation, vendor lifecycle risk, and alignment with clinical goals. That means when a hospital system asks “which AI tool do we pick?”, Bridge can objectively assess competing options, map them to return-on-investment and sustainability, and deliver a clear recommendation (with an implementation roadmap) rather than leaving the client to sort through marketing claims alone.
AI Strategy
Bridge Oncology doesn’t treat AI as a standalone initiative—it treats it as a strategic lever within the broader oncology practice ecosystem: workflow, staffing, reimbursement, modality mix, and patient access. Our strategy competence includes scenario-planning (e.g., if SBRT volume grows, or intra-op radiotherapy is added), linking that to AI enablement (e.g., auto-contouring, predictive scheduling). The ability to view AI through the lens of service-line growth, reimbursement risk, and operational cost gives our clients a sustainable competitive advantage—and that’s rare in purely tech-driven AI consultancies.
AI Thought Leadership
Bridge Oncology is not just implementing AI; we’re actively engaged in thought leadership at the intersection of oncology, workflow, and AI. We produce content, speak in forums, and publish insights that help shape how radiation oncology practices evaluate and deploy AI. That positions us not just as vendors or implementers, but as trusted advisors who bring future-state thinking to current challenges. This thought-leadership role builds trust with clients and strengthens our ability to see ahead of market disruptions.
AI Cost Analysis & Value Realization
Deploying AI in oncology isn’t cheap, and without disciplined cost-benefit modelling it can fail to deliver. Bridge Oncology brings strong capability in cost-analysis: modelling implementation cost (software, hardware, staffing, training), projecting service-line shifts, estimating reimbursement impact (e.g., improved throughput, reduced denials, improved documentation), and creating a business-case tied to measurable outcomes. That means our clients can justify AI spend not as hype, but as an investment with quantifiable return—especially important when capital, staffing and reimbursement are under pressure. Our involvement in ongoing R&D partnerships and policy advisory roles gives us an unprecedented window into what’s real—and what’s marketing fiction.
If You’re Evaluating an AI Solution
When considering new software—especially AI—start with grounded due diligence. Look beyond the demo and the buzz. Ask:
- How many active installs exist in comparable settings?
- How long has the company been in the oncology space?
- What is the real total cost of ownership?
- What support infrastructure is provided for clinicians and administrators?
- How quickly can the tool go live—and integrate with your systems?
The Final Takeaway
AI in oncology has reached its inflection point. The market is saturated with hype, yet meaningful innovation is emerging. The challenge is separating the signal from the noise.
At Bridge Oncology, we’re not chasing trends—we’re shaping them.
We’re defining the operational, legal, and financial frameworks that will determine whether AI becomes oncology’s greatest accelerator or its next administrative burden.
There is no one-size-fits-all solution, but there is a right fit for every problem—when you have the right partner to find it.